Idexx Laboratories fell 14.5% in a year. Neogen rose 2.2-fold.

Same industry

IDXX against four same-industry peers, a year at 100

IDXX is down 14.5% in a year. Neogen is up 2.2 times, Lantheus Holdings is up 87.1% and Celldex Therapeutics 21.7%. Of these four, only Intellia Therapeutics (−48.0%) did less. Weekly closes, Oct 10, 2025 = 100, on a log scale so a 2.2-fold rise and a 48.0% fall both read honestly.

Share this chart

IDXX −14.5%. Neogen ×2.2, Lantheus Holdings +87.1%, Celldex Therapeutics +21.7%, Intellia Therapeutics −48.0%. Weekly closes, Oct 10, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in IDXX’s SEC industry (In Vitro & In Vivo Diagnostic Substances) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

IDXX: stories, the record and filings →